BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide fifteen amino acids long, derived from part of a protective protein found in human gastric juice. In animal studies — overwhelmingly rats — it appears to speed healing in a range of tissues: tendons, the gut lining, muscle and nerve. The most consistent explanation researchers offer is that it helps the body grow new blood vessels into an injury site through a pathway centered on a receptor called VEGFR2 ^[4].

Here is where honesty matters: almost all of this evidence is in animals. As of 2025 narrative reviews, only a small handful of human pilot studies exist, and no large, rigorous, controlled human trials have been published ^[2]. A 2025 first-in-human safety pilot gave intravenous BPC-157 to two healthy adults and found it well tolerated at the tested levels, but two people is not a trial ^[1]. BPC-157 is not approved as a drug anywhere, is prohibited in competitive sport, and popular online claims about weight loss or testosterone are not supported by the published science ^[2].

This page summarizes what was studied. It does not give medical advice and does not list a human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — pentadecapeptide meaning fifteen amino acids, and "stable gastric" because the sequence derives from a cytoprotective (cell-protecting) protein in gastric juice and resists stomach-acid breakdown better than many peptides. Its amino-acid sequence runs Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it is catalogued in the research literature under designations including PL 14736, PLD-116 and PL-10. It is a fully synthetic compound — not something you can extract from food — and it carries the molecular formula C62H98N16O22.

In the regulatory framework it is classified as a research chemical. In 2023 the FDA identified BPC-157 as not eligible for pharmacy compounding under bulk drug substance rules pending further evaluation. It is sold only for laboratory research use.

How it works: the cytoprotective signaling pathway

The most thoroughly characterized mechanism is angiogenesis — the formation of new blood vessels. A 2017 study spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells found that BPC-157 upregulated VEGFR2 expression and promoted VEGFR2 internalization, switching on the downstream VEGFR2-Akt-eNOS (nitric oxide) signaling cascade; blocking that internalization blocked the effect ^[4]. In plain terms: the peptide appears to sensitize blood-vessel cells to the body's own "grow vessels here" signal and accelerated blood-flow recovery in a blocked-circulation muscle model ^[4].

Additional reported pathways include FAK-paxillin signaling (cell migration into wounds), growth-hormone-receptor sensitization in tendon fibroblasts, and modulation of the nitric-oxide system and several neurotransmitter circuits. The pattern is a peptide that nudges multiple repair-related signals at once rather than hitting a single dedicated target.

What makes BPC-157 distinct within the research-peptide field is this cytoprotective framing — it is not a hormone, not an immune regulator, not a metabolic modulator. It appears to promote structural repair at the tissue level by facilitating the supply of blood and the scaffold of new tissue, primarily through angiogenic signaling ^[4][5].

What the research shows

Foundational gut cytoprotection. Early work in Wistar rats found BPC-157 reduced gastric ulcer area and accelerated ulcer healing; intramuscular delivery outperformed intragastric, and ulcer-formation inhibition ratios were approximately 46-66% at higher tested concentrations ^[5]. This gastroprotective origin is where the compound gets its name.

Angiogenesis mechanism. The key mechanistic study (2017) confirmed VEGFR2-mediated pro-angiogenic effects across three experimental models, linking the observed healing to new vessel growth rather than purely anti-inflammatory action ^[4].

Pharmacokinetics. The first formal pharmacokinetic characterization, conducted in rats and beagle dogs (2022), found linear kinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (~14-19% in rats, ~45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism ^[3]. The short half-life means intact peptide does not persist in circulation for long.

Human evidence. It is thin. A 2025 safety pilot gave intravenous BPC-157 up to 20 mg to two healthy adults — a 58-year-old man and a 68-year-old woman — and reported no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose markers ^[1]. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine concludes that "only three pilot studies have examined BPC-157 in humans" and that "rigorous, large-scale trials are lacking," recommending the compound be treated as investigational ^[2].

Reported effects, cautions and safety

Anecdotal community reports (anecdotal, not clinical evidence): People in research-use communities most commonly report faster recovery from tendon, ligament and joint injuries — stubborn problems like tennis elbow or rotator-cuff strains feeling more usable within one to three weeks. Less joint stiffness and pain is frequently described. Improved digestive symptoms (less bloating, cramping) is also commonly reported, which maps intuitively to the compound's gastric origin. Occasionally people note faster wound healing, better sleep or a general sense of reduced inflammation. On the adverse side, brief injection-site redness or stinging is the most common complaint; mild nausea, transient fatigue in the first week, headache, and occasional lightheadedness are also reported. Heart palpitations appear rarely and are a reason to stop use and seek medical evaluation. These are self-reported impressions from research-use communities, not results from controlled human trials.

Literature-grounded cautions:

• The human evidence is extremely thin. Animal results should not be read as proven benefits in people ^[2].
• A large share of foundational research originates from a single group, limiting independent replication — newer reviewers explicitly flag this ^[2].
• BPC-157 is not an approved drug; unregulated products carry unverified identity, purity and dose.
• A theoretical concern exists for people with active or suspected cancer: the peptide's strong pro-angiogenic mechanism could in principle support tumor vasculature ^[4].
• Possible interaction with serotonin-affecting medicines based on rodent neurotransmitter data.
• BPC-157 is prohibited in sport at all times by the World Anti-Doping Agency under the S0 non-approved-substances category.
• No safety data exist for pregnancy, breastfeeding or children.

Where it fits in Research Peptide Fundamentals

Among the four peptides on this desk, BPC-157 represents the cytoprotective class — peptides that promote structural repair rather than triggering hormone release, modulating metabolism, or directing immune responses. It is the most preclinically prolific of the four and the most tissue-general in its reported scope.

Compared with Ipamorelin, which works upstream in the growth-hormone axis, BPC-157 acts more directly at the tissue level — promoting vessel growth rather than signaling the pituitary. Compared with Retatrutide, whose mechanisms are metabolic and hormonal, BPC-157 operates closer to the wound itself. Compared with Thymosin Alpha-1, which modulates immune-cell behavior, BPC-157 is less about immune orchestration and more about structural healing infrastructure.

Its central limitation is the same as its central appeal: decades of animal data with almost no controlled human trials. See the compare page for a structured side-by-side.